Table 1 The characteristics of 141 advanced breast cancer patients in baseline samples
|  | HR + (N = 58) | HER2 + (N = 44) | TN (N = 39) | Overall (N = 141) |
|---|---|---|---|---|
Age, median (range) | 46.0 (29.0, 77.0) | 52.0 (27.0, 76.0) | 48.0 (21.0, 73.0) | 48.0 (21.0, 77.0) |
Tumour grade | ||||
 I | 2 (3.4%) | 1 (2.3%) | 1 (2.6%) | 4 (2.8%) |
 II | 41 (70.7%) | 28 (63.6%) | 16 (41.0%) | 85 (60.3%) |
 III | 8 (13.8%) | 9 (20.5%) | 18 (46.2%) | 35 (24.8%) |
 Unknown | 7 (12.1%) | 6 (13.6%) | 4 (10.2%) | 17 (12.1%) |
Ki67 (%) | ||||
 1–14 | 10 (17.2%) | 1 (2.3%) | 3 (7.7%) | 14 (9.9%) |
 15–25 | 12 (20.7%) | 8 (18.2%) | 5 (12.8%) | 25 (17.7%) |
 26–50 | 19 (32.8%) | 19 (43.2%) | 13 (33.3%) | 51 (36.2%) |
 > 50 | 11 (19.0%) | 13 (29.5%) | 10 (25.6%) | 34 (24.1%) |
 Unknown | 6 (10.3%) | 3 (6.8%) | 8 (20.5%) | 17 (12.1%) |
Primary TNM stage | ||||
 I | 6 (10.3%) | 3 (6.8%) | 9 (23.1%) | 18 (12.8%) |
 II | 19 (32.8%) | 12 (27.3%) | 13 (33.3%) | 44 (31.2%) |
 III | 17 (29.3%) | 12 (27.3%) | 8 (20.5%) | 37 (26.2%) |
 IV | 13 (22.4%) | 13 (29.5%) | 8 (20.5%) | 34 (24.1%) |
 Unknown | 3 (5.2%) | 4 (9.1%) | 1 (2.6%) | 8 (5.7%) |
Adjuvant CT | ||||
 No | 3 (5.2%) | 3 (6.8%) | 0 (0%) | 6 (4.3%) |
 Primary IV | 9 (15.5%) | 12 (27.3%) | 7 (17.9%) | 28 (19.9%) |
 E-based | 13 (22.4%) | 4 (9.1%) | 6 (15.4%) | 23 (16.3%) |
 T-based | 4 (6.9%) | 5 (11.4%) | 7 (17.9%) | 16 (11.3%) |
 E + T | 28 (48.3%) | 20 (45.5%) | 15 (38.5%) | 63 (44.7%) |
 Unknown | 1 (1.7%) | 0 (0%) | 4 (10.3%) | 5 (3.5%) |
Adjuvant ET | ||||
 No | 19 (32.8%) | 28 (63.6%) | 30 (76.9%) | 77 (54.6%) |
 SERM | 21 (36.2%) | 7 (15.9%) | 3 (7.7%) | 31 (22.0%) |
 AI | 10 (17.2%) | 9 (20.5%) | 2 (5.1%) | 21 (14.9%) |
 SERM + AI | 5 (8.6%) | 0 (0%) | 0 (0%) | 5 (3.5%) |
 Unknown | 3 (5.2%) | 0 (0%) | 4 (10.3%) | 7 (5.0%) |
Adjuvant RT | ||||
 No | 37 (63.8%) | 29 (65.9%) | 24 (61.5%) | 90 (63.8%) |
 Yes | 21 (36.2%) | 15 (34.1%) | 11 (28.2%) | 47 (33.3%) |
 Unknown | 0 (0%) | 0 (0%) | 4 (10.3%) | 4 (2.8%) |
PFS (months) | ||||
 Median (range) | 9.76 (0.9, 52.5) | 9.0 (1.8, 39.0) | 5.3 (1.0, 22.0) | 8.0 (0.9, 52.5) |
 12–24 | 10 (17.2%) | 7 (15.9%) | 4 (10.3%) | 21 (14.9%) |
 25–36 | 2 (3.4%) | 2 (4.5%) | 0 (0%) | 4 (2.8%) |
 > 36 | 2 (3.4%) | 1 (2.3%) | 0 (0%) | 3 (2.1%) |
 < 12 | 42 (72.4%) | 30 (68.2%) | 31 (79.5%) | 103 (73.0%) |
 Unknown | 2 (3.4%) | 4 (9.1%) | 4 (10.3%) | 10 (7.1%) |